Longevity Projects funded by VitaDAO

VitaDAO primarily funds translational R&D. We are particularly interested in ‘moonshots’ – potential revolutionary contributions to science. On occasion, we will also fund more ‘basic’ research and other projects in the interests of the LongBio community.

If you’re not sure whether your project is a good fit for VitaDAO funding, you can read our project submission FAQ below, or connect with the VitaDAO Discord community for guidance.

Submit your project
VitaDAO primarily funds translational R&D. We are particulary interested in ‘moonshots’ – potential
revolutionary contributions to science. On occasion we will also fund more ‘basic’ research and
other projects in the interests of the LongBio community.

If you’re not sure whether your project is a good fit for VitaDAO funding, you can read our
project submission FAQ below, or connect with the VitaDAO Discord community for guidance.
100+
Projects Evaluated
$4m+
Funding Deployed
17+
Research Projects Funded
Featured Projects
IP-NFTs & Research Projects

ApoptoSENS - Senolytic CAR-NK Cells

IP-NFT

Senescent cells accumulate with age and are associated with numerous diseases. Dr. Amit Sharma’s team have identified senescence-specific cell surface biomarkers which will act as targets for developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells aiming to precisely and safely eliminate senescent cells in vivo.

$ 253,000
raised
View Project

Discovery of novel mitophagy activators for Alzheimer’s disease

IP-NFT

Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age and is thought to be a driver of Alzheimer’s and other age-related diseases. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.

$ 300,000
raised
View Project

Scheibye-Knudsen Lab

IP-NFT

What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.

$ 250,000
raised
View Project

Reversing periodontal disease using Geroscience: Jonathan An

IP-NFT

The greatest underlying risk factor for periodontitis is age, and its association with other age-related diseases. Jonathan An’s lab proposes to test a series of compounds targeting inflammation in a mouse model of age-related periodontitis, with the goal of finding a geroscience-based treatment for this neglected disease that has a severe impact on human healthspan.

$330,000
raised
View Project

Korolchuk Lab

IP-NFT

Korolchuck lab proposes a drug discovery programme with the aim of identifying novel bioactive autophagy inducers. Activation of autophagy is considered a promising therapeutic approach to combat ageing and age-related diseases.

$ 285,000
raised
View Project

Probing DNA Quadruplexes in Age Related Proteostasis

IP-NFT

This project explores the role of DNA Helicases (WRN and BLM) and DNA quadruplexes (G4) structures in healthy and unhealthy aging and probing both the wanted and unwanted G4 structures and their impact on proteostasis maintenance, which may create the opportunity for novel drug targets.

$ 50,000
raised
View Project
Equity Deals

ImmuneAge Bio - Rejuvenation of aged HSCs

Equity

ImmuneAGE Bio is the first drug discovery platform company focused on immune system rejuvenation. ImmuneAGE rejuvenates hematopoietic stem cells (HSCs) from the bone marrow based on a geroscience screening platform enabled by a new ‘StemSupply’ method achieving >1000x expansion of HSCs.

50,000
raised
View Project

Turn Biotechnologies

Equity

Turn Bio develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. They are reprogramming the epigenome – a network of chemical compounds and proteins controlling cell functions to restore capabilities that are lost with age.

$ 1,000,000
raised
View Project

Rubedo.Life

Equity

Rubedo is building a platform for longevity medicines using “smart drugs” (prodrugs) that have the capacity to selectively be activated in target cells predicted to be pathogenic and the cause of age-related diseases.

$ 350,000
raised
View Project

Etheros - Fullerene Chemistry for Longevity

Equity

Etheros is developing a new class of small molecule drugs based on fullerene chemistry. The lead compound has shown to extend mouse lifespan, improve cognition in elderly mice, and has been neuroprotective in various animal studies. The compounds mimic enzymes that protect cells from oxidative and inflammatory injury. The current raise will help Etheros improve its IP portfolio

$ 50,000
raised
View Project

Repair Biotechnologies

Equity

Repair Biotechnologies is a preclinical-stage biotech company developing a first-in-class universal cell therapy for atherosclerosis. It aims to reduce the risk of cardiovascular events, such as heart attack and stroke.

$ 50,000
raised
View Project

Hyperspectral Imaging for AD

Equity

Mantis Photonics AB is developing a hyperspectral camera for retinal imaging for the early screening of Alzheimer Disease via the detection of the Amyloid beta peptide. The retina displays similarities to the brain and spinal cord in terms of anatomy, functionality and response to insult, hence, the eye providing a unique window to the central nervous system.

30,000 EUR
raised
View Project

Longevity Hackers Film Participation

Equity

A groundbreaking documentary examining the latest research and scientific breakthroughs in the field of longevity and healthy life extension. Featuring wide-ranging interviews from the researchers leading the charge to longevity critics, the film aims to educate and raise awareness, whilst providing a balanced analysis of this exciting and pioneering space.

100,000
raised
View Project
Grants

Support of Clinical Trial - The Effect of Regular Exercise & Intermittent Rapamycin Dosing

Grant

This clinical trial aims to investigate whether periods of time where the mechanistic target of Rapamycin (mTOR) pathway is activated via exercise, combined with alternate periods of time where mTOR is inhibited using Sirolimus (Rapamycin), will result in greater muscle performance in older adults compared with just exercise alone.

$ 50,000
raised
View Project
Other initiatives
Stay tuned for updates coming soon!

Are you working on the next longevity science breakthrough?

Frequently Asked Questions

Who can apply?
What types of projects do you fund?
What is the application structure?
Who owns IP from funded projects?
What project stages do you fund?